more accurate and prompt responses.
REPORT | T&R Biofab Announces Research Collaboration for 3D Bio-printed Surgical Solution | DATE : 2022.08.12 | VIEW : 2300 |
---|---|---|---|
T&R Biofab (246710, CEO: Wonsoo Yun), a leading Tissue Engineering and Regenerative Medicine company, signed a research collaboration agreement facilitated by Johnson & Johnson Innovation to develop a 3D bio-printed surgical solution.
This new feasibility study aims to develop an innovative 3D bio-printed surgical solution for tissue repair surgery.
The technology is based on T&R Biofab’s platform, which can use various biocompatible and biodegradable polymers ranging from synthetic to natural sources.
3D bio-printed surgical solutions can potentially provide support for tissue repair surgery by overcoming disadvantages of conventional materials, and could theoretically offer advantages in terms of mechanical properties, biological stability, and many other parameters.
Dr. Wonsoo Yun, CEO of T&R Biofab, said “this newly signed collaboration is just one of the results of the hard work which enabled a solid foundation and a trusting relationship between our companies”
About T&R Biofab T&R Biofab, founded in 2013, is a science-driven and product-oriented company which has developed and produced their own 3D bio-printing system for the creation of biodegradable scaffolds, bio-ink, 3D organoid models, cytotherapeutic agents, and artificial organs. T&R is a key player contributing major innovations in the field of regenerative medicine, with several of its products already commercialized and currently being used on patients. |